Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Total Liabilities
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has total liabilities worth CN¥1.17 Billion CNY (≈ $171.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002262 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Jiangsu Nhwa Pharmaceutical Co Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Jiangsu Nhwa Pharmaceutical Co Ltd's balance sheet.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BankUnited Inc
NYSE:BKU
|
USA | $31.88 Billion |
|
Sichuan Chemical Co Ltd
SHE:000155
|
China | CN¥14.81 Billion |
|
BBB Foods Inc.
NYSE:TBBB
|
USA | $22.83 Billion |
|
Tofas Turk Otomobil Fabrikasi AS
IS:TOASO
|
Turkey | TL150.07 Billion |
|
Almonty Industries Inc
TO:AII
|
Canada | CA$249.28 Million |
|
EQB Inc.
TO:EQB
|
Canada | CA$48.97 Billion |
|
Salzgitter AG
XETRA:SZG
|
Germany | €6.25 Billion |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
China | CN¥2.59 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Jiangsu Nhwa Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Nhwa Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total liabilities of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.20 Billion ≈ $174.92 Million |
+2.47% |
| 2024-12-31 | CN¥1.17 Billion ≈ $170.69 Million |
+27.06% |
| 2023-12-31 | CN¥918.09 Million ≈ $134.35 Million |
+2.30% |
| 2022-12-31 | CN¥897.43 Million ≈ $131.32 Million |
+13.10% |
| 2021-12-31 | CN¥793.45 Million ≈ $116.11 Million |
+12.28% |
| 2020-12-31 | CN¥706.67 Million ≈ $103.41 Million |
+18.43% |
| 2019-12-31 | CN¥596.68 Million ≈ $87.31 Million |
-44.48% |
| 2018-12-31 | CN¥1.07 Billion ≈ $157.26 Million |
+27.90% |
| 2017-12-31 | CN¥840.24 Million ≈ $122.95 Million |
-1.26% |
| 2016-12-31 | CN¥850.97 Million ≈ $124.52 Million |
+17.60% |
| 2015-12-31 | CN¥723.60 Million ≈ $105.89 Million |
-16.21% |
| 2014-12-31 | CN¥863.61 Million ≈ $126.37 Million |
+18.28% |
| 2013-12-31 | CN¥730.13 Million ≈ $106.84 Million |
+10.22% |
| 2012-12-31 | CN¥662.41 Million ≈ $96.93 Million |
+23.22% |
| 2011-12-31 | CN¥537.59 Million ≈ $78.67 Million |
+9.32% |
| 2010-12-31 | CN¥491.74 Million ≈ $71.96 Million |
+27.83% |
| 2009-12-31 | CN¥384.68 Million ≈ $56.29 Million |
-0.25% |
| 2008-12-31 | CN¥385.66 Million ≈ $56.43 Million |
-13.22% |
| 2007-12-31 | CN¥444.39 Million ≈ $65.03 Million |
+16.44% |
| 2006-12-31 | CN¥381.63 Million ≈ $55.85 Million |
+6.86% |
| 2005-12-31 | CN¥357.12 Million ≈ $52.26 Million |
-- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more